Dendreon Corp. (NASDAQ: DNDN) is trading higher on word from the company that it has filed its new drug application with the FDA for PROVENGE to treat prostate cancer. The notion of the filing is not new, although many were not expecting this filing to be submitted until later in November or in December. At 8:44 AM EST we have seen 250,000 shares trade hands and the last print seen was up 6.8% at $27.00 after a $25.27 close on Friday. Average volume is almost 3 million shares, but it is usually much higher trading volume on days with news.
JON C. OGG
No comments:
Post a Comment